The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1210-1216 , December 2009

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

  • Bob Lanier, MD

      Affiliations

    • Department of Pediatrics, University of North Texas, Fort Worth, Tex
    • Corresponding Author InformationReprint requests: Bob Lanier, MD, Department of Pediatrics, University of North Texas, 6407 Southwest Blvd, Fort Worth, TX 76132.
    • ,
  • Tracy Bridges, MD

      Affiliations

    • Allergy and Asthma Clinics of Georgia, Albany, Ga
    • ,
  • Marek Kulus, MD

      Affiliations

    • Department of Pediatric Respiratory Diseases and Allergy, Medical University of Warsaw, Warsaw, Poland
    • ,
  • Angel Fowler Taylor, RPh

      Affiliations

    • Novartis Pharmaceutical Corp, East Hanover, NJ
    • ,
  • Indrias Berhane, PhD

      Affiliations

    • Novartis Pharmaceutical Corp, East Hanover, NJ
    • ,
  • Carlos Fernandez Vidaurre, MD

      Affiliations

    • Novartis Pharmaceutical Corp, East Hanover, NJ

Received 5 June 2009 ,Revised 9 September 2009 ,Accepted 15 September 2009.

References 

  1. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Gotz M, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008;63:5–34
  2. Environmental Protection Agency. Asthma facts. EPA 402-F-04–019. Available at: http://www.epa.gov/asthma/pdfs/asthma_fact_sheet_en.pdf2008;Accessed June 3, 2009
  3. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16:802–807
  4. Bush A, Hedlin G, Carlsen K-H, et al. Severe childhood asthma: a common international approach?. Lancet. 2008;372:1019–1021
  5. National Heart, Lung and Blood Institute/National Asthma Education and Prevention Program (NHLBI/NAEPP 2007). Expert Panel Report 3: guidelines for the diagnosis and management of asthma. NIH Publication No. 07-4051. Bethesda (MD): US Department of Health and Human Services. Public Health Service. National Institutes of Health, National Heart, Lung, and Blood Institute; 2007;
  6. Chipps BE, Szefler SJ, Simons FE, Haselkorn T, Mink DR, Deniz Y, et al. Demographic and clinical characteristics of children and adolescents with severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2007;119:1156–1163
  7. Bousquet J, Ben Joseph R, Messonnier M, et al. A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther. 2002;24:1–20
  8. Holt S, Suder A, Weatherall M, et al. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001;323:1–8
  9. Randell TL, Donaghue KC, Ambler GR, Cowell CT, Fitzgerald DA, van Asperen PP. Safety of the newer inhaled corticosteroids in childhood asthma. Paediatr Drugs. 2003;5:481–504
  10. Allen DB. Safety of inhaled corticosteroids in children. Pediatr Pulmonol. 2002;33:208–220
  11. Ekins Daukes S, Simpson CR, Helms PJ, Taylor MW, McLay JS. Burden of corticosteroids in children with asthma in primary care: retrospective observational study. BMJ. 2002;324:1374
  12. Larsen GL. Differences between adult and childhood asthma. Dis Mon. 2001;47:34–44
  13. Gelfand EW. Is asthma in childhood different from asthma in adults? why do we need special approaches to asthma in children?. Allergy Asthma Proc. 2008;29:99–102
  14. Paull K, Covar R, Jain N, Gelfand EW, Spahn JD. Do NHLBI lung function criteria apply to children? a cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999-2002. Pediatr Pulmonol. 2005;39:311–317
  15. Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med. 2004;170:426–432
  16. Global Initiative for Asthma. Global strategy for asthma management and prevention. Issued January 1995 (NIH Publication No. 02-3659); updated 2002, 2003, 2004, 2005, 2006, 2007. Available at: http://www.ginasthma.org2007;Accessed June 3, 2009
  17. Xolair (omalizumab) full prescribing information. July 2008. Available at: http://www.xolair.com/prescribing_information.html. Accessed July 29, 2008.
  18. Xolair (omalizumab) product information (summary of product characteristics—annex I). May 2007. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/xolair/xolair.htm. Accessed July 29, 2008.
  19. Bousquet J, Cabrera P, Berkman N, Buhl R, Holgate S, Wenzel S, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005;60:302–308
  20. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190
  21. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009 Mar 17;[epub ahead of print]
  22. Holgate ST, Chuchalin AG, Hebert J, Lotvall J, Persson GB, Chung KF, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632–638
  23. Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309–316
  24. Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol. 2003;91:154–159
  25. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. [published correction appears in Eur Respir J 2001;18:739-740] Eur Respir J. 2001;18:254–261
  26. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics. 2001;108:E36
  27. National Institute of Health, National Heart, Lung and Blood Institute (NHLBI guidelines) NIH Publication No. 02-4051, updated July 2002 by National Asthma Education and Prevention Program (NAEPP) Publication No. 02–5075.
  28. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5:35–46
  29. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst. 1960;37:351–361
  30. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800–802
  31. MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997;158:1438–1445
  32. Chipps B, Buhl R, Beeh K-M, et al. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin. 2006;22:2201–2208
  33. Kelly HW, Van Natta ML, Covar RA, et al. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood asthma management program (CAMP) study. Pediatrics. 2008;122:e53–e61
  34. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med. 1998;157:S1–S53
  35. Adams NP, Jones PW. The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med. 2006;100:1297–1306
  36. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144:904–912
  37. Mann M, Chowdhury B, Sullivan E, et al. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124:70–74
  38. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics. 2005;116:360–369
  39. Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2004;(2):CD002314
  40. Ostrom NK, Decotiis BA, Lincourt WR, Edwards LD, Hanson KM, Carranza R, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr. 2005;147:213–220
  41. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115:233–242

 Supported by Novartis Pharma AG.

 Disclosure of potential conflict of interest: B. Lanier has served as a consultant for Alcon Laboratories and has received research support from Alcon Laboratories, Genentech/Novartis, and AstraZeneca. T. Bridges has served on the speakers' bureau and has received research support from Novartis and Genentech. The rest of the authors have declared that they have no conflict of interest.

 ClinicalTrials.gov Identifier: NCT00079937

PII: S0091-6749(09)01409-2

doi: 10.1016/j.jaci.2009.09.021

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1210-1216 , December 2009

Article Tools

* Image Usage & Resolution